Source: The Calmer Co International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

When microcap consumer health brand stock Calmer Co (ASX:CCO) stacked its products on the shelves at Coles (ASX:COL), it knew it was onto a good thing.

But the results from the initial launch period were, perhaps, above expectations – Coles scan sales for CCO’s line of kava-based health drinks, advertised as being able to calm down the mind and body, have clocked $150K.

Broken down by week, the company saw more than $30K in sales every seven days and over 4,600 units sold per week in the eighth week following touchdown on the shelves.

E-commerce sales broadly, meanwhile, now fetch Calmer Co over $11,000 per day.

While the Coles sales performance could be viewed as impressive, company chief Anthony Noble underscored the importance of ecommerce avenues broadly to the company’s bottom line.

Calmer Co has a presence on the e-commerce platforms of Amazon and Walmart.

“Excellence in ecommerce is our primary growth pillar. We have continued to grow month-on-month in these channels, with both Shopify and Amazon contributing,” Noble observed.

“Shopify USA sales in April were more than 4x the March baseline indicating that our strategy in the USA is showing similar promising signs to the early days in the Australian market for Shopify.

“Profitable Retail is our second growth pillar and Coles Australia has been our primary
partner in this channel. The initial sales results seen for the new range of three products in Coles are extremely promising.”

CCO last traded at 0.6cps.

CCO by the numbers
More From The Market Online

Keystone US Navy supply chain firm picks up AML3D’s 3D-print tech

Defence-focused metals-based 3D printing tech company AML3D has confirmed a US Navy supplier has leased its…

Canberra greenlights Maximus for Korean firm’s 30% farm-in at Lefroy

Maximus Resources has received approval from Canberra for a Korean mining firm to farm-in for 30%…

Telix Pharma gears up to launch US IPO

Telix Pharmaceuticals has announced it's working with Morgan Stanley to list depository shares on the NASDAQ.

Market Open: ASX200 set to rise as VIX hits 5-year-low

Good morning. It’s looking like a good start to the week on the futures market with…